UNSPSC 51352406: Drospirenone/ethinyl estradiol/levomefolate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352406 Drospirenone/ethinyl estradiol/levomefolate (Commodity) encompasses birth-control and hormone-therapy pharmaceutical products that state and local health systems, Medicaid programs, and employee health plans procure through pharmacy benefit programs and cooperative purchasing arrangements. Recent solicitations show state health agencies and multistate purchasing alliances treating this Commodity as part of broader generic pharmaceutical procurement portfolios rather than as a standalone product line, bundling it with other multi-source generics and over-the-counter items under consolidated supply contracts managed through authorized wholesalers. Issuing bodies include state health and human services departments (such as the Texas Health and Human Services Commission), state procurement offices administering multistate cooperative purchasing alliances (such as the Minnesota Multistate Cooperative Purchasing Alliance), and participating state and local government facilities across multiple jurisdictions. Vendors responding to opportunities at this Commodity level typically operate as manufacturers holding current Good Manufacturing Practices certifications and Drug Supply Chain Security Act compliance, with direct contractual relationships to at least two of the three major authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and chargeback systems in place.

Recent activity centers on Texas and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program intended to circumvent traditional pharmacy benefit managers and group purchasing organizations in favor of direct state contracts with manufacturers for self-insured plans. The Minnesota Department of Administration's Office of State Procurement, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating facilities in Minnesota and Oregon, with awarded vendors required to supply through authorized wholesalers beginning July 1, 2026, and pricing evaluated at 75 percent weight with compliance and administrative fees comprising the remainder. No specific budget or award value is disclosed in either solicitation; the MMCAP RFP imposes a 3 percent administrative fee on contract purchases and performance penalties ranging from $200 to $1,500 per violation.